Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-22T08:30:28.689Z Has data issue: false hasContentIssue false
  • English
  • Français

Risk and Crisis Communication Recommendations for Industry Based on Advances in Cognitive Behavioral Science Research

Published online by Cambridge University Press:  20 January 2017

Sweta Chakraborty
Sweta Chakraborty*
Affiliation:
Lootok Ltd.
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Reports
Information
European Journal of Risk Regulation , Volume 5 , Issue 2 , June 2014 , pp. 238 - 241
Copyright
Copyright © Cambridge University Press 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Fischhoff, B. (2007).‘Risk perception and communication.’ In: Ayers, S. et al. (eds). Cambridge Handbook of Psychology, Health and Medicine. p. 190. Cambridge: Cambridge University Press.Google Scholar

2 Slovic, P. (1987). Perception of Risk. Science. p. 236.Google ScholarPubMed

3 Kasperson, JX, Kasperson, RE, Eds. (2005). The Social Contours of Risk. Earthscan.Google Scholar

4 Fischhoff, B., Slovic, P., et al. (1978). How Safe is Safe Enough? A Psychometric Study of Attitudes Towards Technological Risks and Benefits. Policy Sciences. p. 127–52.CrossRefGoogle Scholar

5 Slovic, et al. (2007). Risk Perception of Prescription Drugs: Results of a National Survey. Drug Information Journal. 41: p. 81–100.CrossRefGoogle Scholar

6 Fischhoff, B. (1995). Risk Perception and Communication Unplugged: Twenty Years of Process. Risk Analysis. p. 137–45.CrossRefGoogle Scholar

7 Sandman, P. (2005). Terrorism and Other Public Health Emergencies: A Reference Guide for the Media. Washington, DC: U.S. Department of Health & Human Services. Chapter 11: p. 184–193.Google Scholar

8 Morgan, G. M., Fischhoff, B, Bostrom, A, Atman, C J. (2002). Risk Communication: A Mental Models Approach. Cambridge University Press.Google Scholar

9 Ibid.

10 Conzelmann, T. (2007). External Transparency and Internal Viability. Paper presented at the annual meeting of the International Studies Association 48th Annual Convention ; Hilton Chicago: Chicago, IL.Google Scholar

11 Chakraborty, S, Lofstedt, R. (2012). Transparency Initiative by the FDA's Center for Drug Evaluation and Research (CDER): Two qualitative studies of Public Perceptions. EJRR. 3(1): p. 57–71.Google Scholar

12 Fung, A, Graham, M, Weil, D. (2007). Full Disclosure: The perils and promise of transparency. Cambridge: Cambridge University Press.CrossRefGoogle Scholar

13 Chakraborty, S. (2012a). Part 1: The Role of Trust in Patient Non-Compliance: A Qualitative Case Study of Users of Statins for the Chronic Treatment of High-Cholesterol in New York City. Journal for Risk Research. 16(1): p. 97–112.CrossRefGoogle Scholar

14 Chakraborty, S. (2012b). Part 2: The Role of Trust in Patient Non-Compliance: A Quantitative Case Study of Users of Statins for the Chronic Treatment of High-Cholesterol in New York City. Journal for Risk Research. 16(1): p. 113–29.CrossRefGoogle Scholar

15 Hilts, PJ. (2003). Protecting America's Health: The FDA, Business, and One Hundred Years of Regulation. New York, Knopf.Google Scholar

16 Bradford, JL, Garrett, DE. (1995). The effectiveness of corporate communicative responses to accusations of unethical behaviour. Journal of Business Ethics. 14(11): p. 875–92.CrossRefGoogle Scholar

17 Lofstedt, R. (2007). The Impact of the Cox-2 Inhibitor Issue on Perceptions of the Pharmaceutical Industry: Content Analysis and Communication Implications. J Health Commun. 12(5): p. 471–91.CrossRefGoogle Scholar

18 US Food and Drug Administration. (2004). FDA Acts to strengthen the safety program for marketed drugs. FDA Statement. Rockville: FDA.Google Scholar

19 Löfstedt, R. (2005). Risk Management in Post Trust Societies. Basingstoke, Palgrave/Macmillan.CrossRefGoogle Scholar

20 Chakraborty, S and Bouder, F. (2013). The Future of Risk Communication and the Role of the Pharmaceutical Industry. Drug Safety. 8(1): p. 4–10.CrossRefGoogle ScholarPubMed